Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01628549 · ClinicalTrials.gov registry record · Phase 2
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
A Phase 2 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
NCT01628549 is a Phase 2 study that has completed, run by Almirall, S.A.. The registered enrollment target is 285 participants.
The verdict
NCT01628549, a Phase 2 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.
Interventions
- DRUG Placebo
- DRUG 50 mg P005672-HCl
- DRUG 100 mg P005672-HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2012-06-30 |
| Est. Completion | 2013-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01628549
The ClinicalTrials.gov registry entry for NCT01628549 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01628549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01628549 about?
NCT01628549 is a clinical study titled "Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris". To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.
What is the current status of trial NCT01628549?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2012-06-30. Estimated completion is 2013-01-31.
What interventions are being tested in trial NCT01628549?
The interventions under investigation include: Placebo (DRUG), 50 mg P005672-HCl (DRUG), 100 mg P005672-HCl (DRUG).
Who is sponsoring clinical trial NCT01628549?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.